Most Recent Posts
It's no secret that the biopharmaceutical sector provides jobs - and a wide range of jobs, at that. We're not just researchers in lab coats. In terms of jobs we support, we're also the drivers of trucks that help medicines reach pharmacies, the construction workers and technicians who help construct the facilities and equipment necessary for manufacture of medicines, and more. Ultimately, it's an intricate web of workers that all play a role in the important work that we do.
A recent editorial in the New York Times delved into some overarching issues around coverage of cancer medicine. While the paper raises some interesting questions, it unfortunately missed a few key considerations in trying to come up with answers.
This week, I had the chance to speak with Dr. Marc S. Ernstoff from Dartmouth College's Dartmouth-Hitchcock Medical Center. Dr. Ernstoff, a leading oncologist and melanoma researcher, took the time to explain to me some of the latest advances in the field.
Tell us how you became involved in melanoma research?
Yesterday, The Hill's Congress Blog ran a column by Nicole Boice, founder and CEO of the Children's Rare Disease Network, about how the Prescription Drug User Fee Act (PDUFA) has helped to bring orphan medicines to pediatric patients.
PhRMA recently released its report on the nearly 300 new medicines now being developed to help fight skin diseases. The report looks at new medicines now in late-stage clinical trials or currently before the FDA for final approval for patient use.
PhRMA recently released its Medicines in Development for Skin Diseases report, which found 74 medicines in development for skin cancers.
Yesterday, representatives from emerging companies spoke at the BIO International Convention about the work they are doing in the field of personalized medicine.
At the end of the day yesterday, R&D experts from an assortment of biopharmaceutical research companies as well as venture capital came together to discuss what the future of the sector will look like from an innovation standpoint.
Speaking at the BIO 2011 International Convention, Jeff Behrens from early-stage company Edimer Pharma discussed the many challenges that orphan drug developers confront in their quest to successfully treat a rare disease.
Today kicks off the Biotechnology Industry Organization's 2011 International Convention. The four-day event is one of the biopharmaceutical research sector's largest gatherings and is sure to generate some interesting coverage.
Yesterday, the Partnership for Safe Medicines - of which PhRMA is one of many members - held a congressional briefing to discuss the threat of rogue online pharmacies to patients in America.